Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. ANVS
stocks logo

ANVS

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Intellectia AI SwingMax
Intellectia AI SwingMax

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
--
--
-0.310
-27.91%
--
--
-0.347
+8.33%
--
--
-0.347
+8.33%
Estimates Revision
Stock Price
Go Up
up Image
+103.06%
In Past 3 Month
Wall Street analysts forecast ANVS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ANVS is 11.67 USD with a low forecast of 8.00 USD and a high forecast of 17.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Analyst Rating
Wall Street analysts forecast ANVS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ANVS is 11.67 USD with a low forecast of 8.00 USD and a high forecast of 17.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Buy
0 Hold
0 Sell
Strong Buy
Current: 4.650
sliders
Low
8.00
Averages
11.67
High
17.00
Current: 4.650
sliders
Low
8.00
Averages
11.67
High
17.00
H.C. Wainwright
H.C. Wainwright
Buy
downgrade
$12 -> $10
2025-09-03
Reason
H.C. Wainwright
H.C. Wainwright
Price Target
$12 -> $10
2025-09-03
downgrade
Buy
Reason
H.C. Wainwright lowered the firm's price target on Annovis Bio to $10 from $12 and keeps a Buy rating on the shares. The firm says the company's buntanetap Alzheimer's disease pivotal trial remains in progress. It cites a lengthier time to potential approval for the target cut.
H.C. Wainwright
H.C. Wainwright
Buy
downgrade
$30 -> $12
2025-06-09
Reason
H.C. Wainwright
H.C. Wainwright
Price Target
$30 -> $12
2025-06-09
downgrade
Buy
Reason
H.C. Wainwright lowered the firm's price target on Annovis Bio to $12 from $30 and keeps a Buy rating on the shares. The firm cites the impact of the most recent equity financing in February of this year, future potential equity issuances and the exercise of warrants for the target cut.
Canaccord
Sumant Kulkarni
Buy
downgrade
$26 -> $17
2025-05-15
Reason
Canaccord
Sumant Kulkarni
Price Target
$26 -> $17
2025-05-15
downgrade
Buy
Reason
Canaccord analyst Sumant Kulkarni lowered the firm's price target on Annovis Bio to $17 from $26 and keeps a Buy rating on the shares. The firm noted the released Q1 results which showed the company initiated its pivotal Phase 3 clinical trial for buntanetap for early Alzheimer's disease (AD). Previously the company had said earlier that it had reached alignment with the FDA on a pivotal trial with a 6-month endpoint focused on symptomatic benefit and an 18-month endpoint to address disease progression in early AD.
D. Boral Capital
Jason Kolbert
Strong Buy
to
Hold
Downgrades
n/a
2025-02-10
Reason
D. Boral Capital
Jason Kolbert
Price Target
n/a
2025-02-10
Downgrades
Strong Buy
to
Hold
Reason
See All Ratings

Valuation Metrics

The current forward P/E ratio for Annovis Bio Inc (ANVS.N) is -3.37, compared to its 5-year average forward P/E of -6.72. For a more detailed relative valuation and DCF analysis to assess Annovis Bio Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-6.72
Current PE
-3.37
Overvalued PE
1.97
Undervalued PE
-15.41

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-0.91
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.30
Undervalued EV/EBITDA
-2.12

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
0.00
Current PS
0.00
Overvalued PS
0.00
Undervalued PS
0.00
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
AI Stock Picker
AI Stock Picker

ANVS News & Events

Events Timeline

(ET)
2025-11-18
09:30:40
Annovis schedules FDA meeting to review PDD program
select
2025-11-17 (ET)
2025-11-17
08:08:18
Annovis Bio Reveals Biomarker Findings Related to Amyloid Co-Pathology in Parkinson's Disease
select
2025-11-12 (ET)
2025-11-12
08:08:03
Annovis Bio projects funding to last until the third quarter of 2026.
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
3.5
12-03Newsfilter
Annovis Bio Presents Parkinson's Disease Therapy Data at PSG Annual Meeting
  • Clinical Data Presentation: Annovis Bio will present Phase 3 data at the 2025 Parkinson Study Group Annual Meeting, revealing that patients with amyloid co-pathology experience more pronounced cognitive decline, which is effectively countered by buntanetap, indicating its potential in treating Parkinson's disease.
  • Biomarker Improvement: The study shows that buntanetap not only reverses cognitive decline but also reduces tau biomarkers associated with disease severity, further validating the drug's mechanism as a translational inhibitor of neurotoxic aggregating proteins.
  • Cross-Study Comparison: The presentation will debut a cross-study comparison of completed trials, providing a comprehensive analysis of cognitive outcomes across all tested indications by Annovis, highlighting that patients with amyloid pathology benefit the most from the treatment.
  • Support for Strategic Steps: These findings support Annovis's next strategic steps, reinforcing its leadership position in neurodegenerative disease treatment and are expected to drive future R&D investments and market expansion.
[object Object]
Preview
5.0
11-18Newsfilter
U.S. Anti-Aging Products Market Driven by Longevity Health Expected to Hit $27 Billion by 2033

  • Market Growth: The anti-aging therapies market is rapidly expanding, projected to grow from USD 14.05 billion in 2024 to USD 27.44 billion by 2033 in the U.S., driven by an aging population and increased consumer interest in preventive health and high-performance skincare solutions.

  • Consumer Preferences: There is a strong demand for anti-aging products containing potent ingredients like retinoids and peptides, with a notable trend towards clean beauty and natural ingredients, as 63% of U.S. consumers prefer products that are good for their skin and the environment.

  • Innovative Collaborations: Avant Technologies and Austrianova have formed a joint venture, Klothonova, to develop Klotho-based therapies for aging, utilizing advanced cell encapsulation technology to enhance treatment efficacy and safety.

  • Biotech Developments: Companies like Recursion, Intellia Therapeutics, Zymeworks, and Annovis Bio are making significant advancements in their respective fields, focusing on leadership transitions, promising clinical trial results, and innovative therapies for various diseases, including neurodegenerative conditions and cancer.

[object Object]
Preview
9.0
11-18Benzinga
Annovis Bio Shares Surge Following New Data Indicating Buntanetap Prevents Cognitive Decline in Parkinson's Patients

  • Stock Performance: Annovis Bio Inc. (ANVS) shares surged 55.91% to $3.65, with a trading volume of 12.29 million, significantly higher than the average of 615.12 thousand.

  • Clinical Study Results: The company reported positive Phase 3 study results for its drug, buntanetap, which halted cognitive decline in early Parkinson’s disease patients, particularly benefiting those with mild dementia.

  • Impact of Amyloid Co-pathology: Approximately 25% of patients with amyloid co-pathology showed more severe cognitive decline, which was reversed by treatment with buntanetap.

  • Biomarker Improvements: The treatment led to significant cognitive improvements and measurable reductions in neurodegeneration biomarkers, reinforcing the interconnected nature of neurodegenerative diseases like Alzheimer’s and Parkinson’s.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Annovis Bio Inc (ANVS) stock price today?

The current price of ANVS is 4.65 USD — it has increased 0 % in the last trading day.

arrow icon

What is Annovis Bio Inc (ANVS)'s business?

Annovis Bio, Inc. is a late-stage clinical drug platform company addressing neurodegeneration such as Alzheimer’s disease (AD), and Parkinson’s disease (PD). The Company is developing its lead product candidate, Buntanetap, which is designed to address AD, PD, and potentially other chronic neurodegenerative diseases. Buntanetap is a synthetically produced small molecule, orally administered, brain penetrant compound. Its product candidate ANVS405 is an intravenous drug being developed for acute indications and focused on protecting the brain after traumatic brain injury and/or stroke. ANVS405 is the same compound as Buntanetap, given in cases of acute head and brain trauma. ANVS301 is an orally administered drug being developed to increase cognitive capability in later stages of AD and dementia. ANVS301 is observed to improve memory and learning in very old rats by lowering the number of errors from over six to three.

arrow icon

What is the price predicton of ANVS Stock?

Wall Street analysts forecast ANVS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ANVS is 11.67 USD with a low forecast of 8.00 USD and a high forecast of 17.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Annovis Bio Inc (ANVS)'s revenue for the last quarter?

Annovis Bio Inc revenue for the last quarter amounts to -7.43M USD, increased 69.45 % YoY.

arrow icon

What is Annovis Bio Inc (ANVS)'s earnings per share (EPS) for the last quarter?

Annovis Bio Inc. EPS for the last quarter amounts to USD, decreased % YoY.

arrow icon

What changes have occurred in the market's expectations for Annovis Bio Inc (ANVS)'s fundamentals?

The market is revising No Change the revenue expectations for ANVS for , with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by 103.06%.
arrow icon

How many employees does Annovis Bio Inc (ANVS). have?

Annovis Bio Inc (ANVS) has 8 emplpoyees as of December 05 2025.

arrow icon

What is Annovis Bio Inc (ANVS) market cap?

Today ANVS has the market capitalization of 123.24M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free